Evidence map›Paper›PMID 37033158›Full record

ArticleDrug and alcohol dependence reports2023

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series.

Taylor A Ochalek, Katy J Ringwood, Theresa T Davis, Tamas S Gal, Brandon K Wills, Roy T Sabo, Lori Keyser-Marcus, Caitlin E Martin, Kathryn Polak, Kirk L Cumpston and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Taylor A OchalekDepartments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA, United States.
Katy J RingwoodDepartments of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States.
Theresa T DavisDepartments of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States.
Tamas S GalDepartments of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, United States.
Brandon K WillsDepartments of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States.
Roy T SaboDepartments of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, United States.
Lori Keyser-MarcusDepartments of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States.
Caitlin E MartinDepartments of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, Virginia, United States.
Kathryn PolakDepartments of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, United States.
Kirk L CumpstonDepartments of Emergency Medicine, Virginia Commonwealth University, Richmond, Virginia, United States.
F Gerard MoellerDepartments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA, United States.
Virginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
Preclinical Assessment of Compounds for Cocaine Use Disorder (CocUD)U54DA038999 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2014 to 2018
$6.8M
Adaptation and Refinement of a Clinically Applicable Phenotypic Battery to Individualize Opioid Use Disorder Treatment for Women Through the Postpartum PeriodK23DA053507 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MARTIN, CAITLIN EILEEN · 2021 to 2025
$1.0M
NCATS NIH HHS UL1 TR002649NCI NIH HHS P30 CA016059NIDA NIH HHS K23 DA053507NIDA NIH HHS T32 DA007027NIDA NIH HHS U54 DA038999
6 · The paper itself

Abstract

Background: Buprenorphine treatment has been associated with reduced non-prescribed opioid use and opioid related overdose (OD). We evaluated initial outcomes of rapid induction onto extended-release injectable buprenorphine (BUP-XR) within 7 days of emergency department presentation for unintentional OD. Methods: Between February 2019-February 2021, Results: For patients who received at least one dose of BUP-XR, there were no treatment related serious adverse events or symptoms of precipitated withdrawal. In addition, there were no repeat visits for ODs or deaths within 6 months of the initial OD. Discussion: These preliminary findings support the need for larger controlled clinical trials to examine the safety and efficacy of rapid induction of BUP-XR in patients with opioid use disorder at high risk of opioid OD. Rapid induction onto long-lasting injectable buprenorphine may be a promising and protective treatment approach in the future.

Indexed as

Addiction medicineBuprenorphineEmergency departmentExtended-release buprenorphineFentanylHealth disparitiesInjectable buprenorphineMedications for opioid use disorderOpioid overdoseOpioid use disorderOverdoseRapid induction

Identifiers

PMID37033158
PMCPMC10073633
OpenAlexW4324316208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.